PATH " RIGHT NOW IN CONVERSATIONS WITH CO'S TO PARTNERSHIP" LINK
NuPathe Wins U.S. FDA Approval for Migraine Skin Patch
By Ryan Flinn - Jan 17, 2013 6:43 PM ET
NuPathe Inc. (PATH), a maker of neurological and psychiatric medicines, won U.S. regulatory approval for the first skin patch to treat migraines.
The Food and Drug Administration cleared the treatment, called Zecuity, which delivers sumatriptan, the most-prescribed migraine headache medication, through a mild electrical current, Conshohocken, Pennsylvania-based NuPathe said today in a statement.
“We anticipate the product will be available for sale in the fourth quarter of this year,” Armando Anido, NuPathe’s chief executive officer, said in an interview. “We’re right now in conversations with a number of people for partnership in the United States.”"